tradmap

AGEN AGENUS INC

$3.00 +1.01%

Healthcare · Biological Products, (No Diagnostic Substances)

AGENUS INC (AGEN) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $125 million. Shares last traded at $3.00, 59.0% below their 52-week high. Over the past year the stock is down 37.0%. Net profit margin is -2.7%, below the peer median of 6.3%. Revenue grew 10.4% year over year.

Market Cap
$125M
Shares Out
41.6M
EPS (TTM)
$-1.67
P/E Ratio
P/S Ratio
1.09
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$7.33
52-Week Low
$2.71
Volume
25,210
Avg Vol (3m)
51,958.825

Performance

1W
-11.76%
1M
-2.91%
3M
-21.05%
6M
-19.68%
YTD
-7.12%
1Y
-36.97%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
40.27
SMA (50)
$3.65
SMA (200)
$3.73
Price vs SMA50
-17.71%
Price vs SMA200
-19.60%
ATR (14)
$0.23

Financials

Revenue
$114M
Net Income
$-3M
Gross Margin
Operating Margin
-17.7%
Net Margin
-2.7%
Return on Equity
1.4%
Return on Assets
-1.7%
Current Ratio
0.38
Debt / Equity
-0.14
Revenue Growth (YoY)
+10.4%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $1.02 2026-05-11
FY 2025 $0.00 2026-03-16
Q3 2025 $0.37 2025-11-10
Q2 2025 $-2.03 2025-08-11
Q1 2026 $-1.03 2026-05-11
FY 2025 $-10.59 2026-03-16

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

AGEN vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
1.09 / 5.21 med
-79% discount
Net margin vs peers
-2.7% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.